000163549 001__ 163549
000163549 005__ 20240722121854.0
000163549 0247_ $$2doi$$a10.3389/fnagi.2022.838674
000163549 0247_ $$2pmid$$apmid:35222002
000163549 0247_ $$2pmc$$apmc:PMC8874137
000163549 037__ $$aDZNE-2022-00305
000163549 041__ $$aEnglish
000163549 082__ $$a610
000163549 1001_ $$0P:(DE-2719)9000916$$aBecker, Sara$$b0
000163549 245__ $$aDivergence Between Informant and Self-Ratings of Activities of Daily Living Impairments in Parkinson's Disease.
000163549 260__ $$aLausanne$$bFrontiers Research Foundation$$c2022
000163549 3367_ $$2DRIVER$$aarticle
000163549 3367_ $$2DataCite$$aOutput Types/Journal article
000163549 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721639699_12031
000163549 3367_ $$2BibTeX$$aARTICLE
000163549 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163549 3367_ $$00$$2EndNote$$aJournal Article
000163549 520__ $$aTo examine the agreement between self- and informant-reported activities of daily living (ADL) deficits in Parkinson's Disease (PD) patients, and to examine factors influencing ADL ratings.In PD, the loss of functional independence is an important outcome of disease progression. The valid assessment of ADL function in PD is essential, but it is unclear to what extent informants' and patients' perceptions of their daily functions concur, and how other factors may influence both ratings.Data of 150 PD patients who underwent cognitive and motor testing, as well as their informants were analyzed. The 10-item Functional Activities Questionnaire (FAQ), completed separately by patients (FAQ-S) and their informants (FAQ-I), assessed ADL function. Weighted κ statistics summarized level of agreement, and a discrepancy score (FAQ-I - FAQ-S) quantified agreement. Correlation analyses between FAQ total scores, patient and informant characteristics, and cognitive scores were conducted, with post hoc regressions to determine the associations between both FAQ scores and cognition, independent of patient characteristics.The sample included 87 patients with normal cognition, 50 with mild cognitive impairment, and 13 with dementia. Overall, there was fair to moderate agreement between patients and informants on individual FAQ items (0.27 ≤ κ ≤ 0.61, p < 0.004), with greater discrepancies with increasing cognitive impairment. Patients' age, motor severity, non-motor burden, and depression also affected both ratings (0.27 ≤ r ≤ 0.50, p < 0.001), with motor severity showing the greatest influence on both ratings. Both the FAQ-I and FAQ-S were correlated with almost all cognitive domains. Post hoc regression analyses controlling for patient characteristics showed that the attention domain was a significant predictor of both the FAQ-S and FAQ-I scores, and memory was also a significant predictor of the FAQ-I score. Only 29.3% of patients agreed perfectly with informants on the FAQ total score, with informants most commonly rating ADL impairments as more severe than patients.Patient and informant ratings of ADL function using FAQ items showed moderate agreement, with only few items reaching substantial agreement. Ratings of both were associated with patient cognitive status, but also other characteristics. In addition to patient and informant reports, objective measures are needed to accurately classify ADL deficits in PD.
000163549 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163549 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163549 650_7 $$2Other$$aFunctional Activities Questionnaire
000163549 650_7 $$2Other$$aParkinson’s Disease
000163549 650_7 $$2Other$$aactivities of daily living
000163549 650_7 $$2Other$$acaregiver
000163549 650_7 $$2Other$$acognition
000163549 650_7 $$2Other$$ainformant-ratings
000163549 650_7 $$2Other$$aself-ratings
000163549 7001_ $$0P:(DE-2719)2810733$$aNußbaum, Susanne$$b1$$udzne
000163549 7001_ $$0P:(DE-2719)9001392$$aMichaelis, Katja$$b2
000163549 7001_ $$0P:(DE-2719)9000070$$aFaust, Bettina$$b3
000163549 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b4
000163549 7001_ $$0P:(DE-2719)2109499$$aLiepelt-Scarfone, Inga$$b5$$eLast author
000163549 773__ $$0PERI:(DE-600)2558898-9$$a10.3389/fnagi.2022.838674$$gVol. 14, p. 838674$$p838674$$tFrontiers in aging neuroscience$$v14$$x1663-4365$$y2022
000163549 8564_ $$uhttps://pub.dzne.de/record/163549/files/DZNE-2022-00305.pdf$$yOpenAccess
000163549 8564_ $$uhttps://pub.dzne.de/record/163549/files/DZNE-2022-00305.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163549 909CO $$ooai:pub.dzne.de:163549$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163549 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000916$$aExternal Institute$$b0$$kExtern
000163549 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810733$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163549 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001392$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163549 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000070$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000163549 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000163549 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2109499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163549 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163549 9141_ $$y2022
000163549 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163549 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000163549 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT AGING NEUROSCI : 2021$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-13T09:17:03Z
000163549 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-13T09:17:03Z
000163549 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-13T09:17:03Z
000163549 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000163549 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT AGING NEUROSCI : 2021$$d2022-11-30
000163549 9201_ $$0I:(DE-2719)1240005$$kCore ICRU$$lCore ICRU$$x0
000163549 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000163549 9201_ $$0I:(DE-2719)5000058$$kExt UKT$$lExt Universitätsklinikum Tübingen$$x2
000163549 980__ $$ajournal
000163549 980__ $$aVDB
000163549 980__ $$aI:(DE-2719)1240005
000163549 980__ $$aI:(DE-2719)1210000
000163549 980__ $$aI:(DE-2719)5000058
000163549 980__ $$aUNRESTRICTED
000163549 9801_ $$aFullTexts